Wearable ECG patches and mobile cardiac telemetry that enable continuous, remote detection of arrhythmias — primarily atrial fibrillation AFib , the most common cardiac arrhythmia affecting 33 million people globally. iRhythm's Zio patch is the dominant platform: a single use, wire free adhesive patch worn for up to 14 days, with AI powered arrhythmia detection and cloud based clinician reporting. The value proposition: replace 24 hour Holter monitors which miss 50% of arrhythmias with long duration monitoring that captures intermittent events.
Remote Cardiac Monitoring technology and investment research
Wearable ECG patches and mobile cardiac telemetry that enable continuous, remote detection of arrhythmias — primarily atrial fibrillation AFib , the most common cardiac arrhythmia affecting 33 million people globally. iRhythm's Zio patch…
Remote Cardiac Monitoring matters because longer, healthier lives depend on repeatable infrastructure—not only successful therapies. Its connection to Maintain makes it a potential toll road for measurement, proof, manufacturing, delivery or recurring care.
Research expansion in progress
Remote Cardiac Monitoring: technology and investment research
950 words · Vault research updated Jul 5, 2026
Technical bottleneck
Why it's a moat — AI accuracy, clinical validation, and EHR integration
Remote cardiac monitoring is an AI diagnostics business dressed as a wearable. The moat has three layers:
1. AI arrhythmia detection accuracy: Zio's deep learning algorithms analyze 14 days of continuous ECG data — millions of heartbeats — and flag clinically relevant arrhythmias (AFib, PVCs, VT, pauses, SVT). The AI reduces the clinician review burden from hours to minutes. Accuracy is the competitive moat: false positives generate unnecessary follow-up (costly and anxiety-inducing); false negatives miss treatable arrhythmias (stroke risk). iRhythm's algorithms improve with every patient — the data flywheel compounds.
2. Clinical validation: Zio has published validation studies demonstrating superior diagnostic yield vs. Holter monitors. This clinical evidence drives guideline recommendations (ACC/AHA, ESC) and payer coverage decisions. A new entrant would need to replicate these studies — a 3–5 year, multi-million dollar clinical trial program — to compete for reimbursement.
3. EHR integration (Aura platform): iRhythm's Aura platform integrates Zio reports directly into Epic and other EHR systems, allowing cardiologists and primary care physicians to order, review, and act on results within their existing workflow. This is a soft but real switching cost — changing cardiac monitoring vendors means disrupting the EHR integration that clinicians have built into their daily practice.
The primary care expansion: Historically, Zio was ordered primarily by cardiologists and electrophysiologists. iRhythm is now targeting primary care — the front door for undiagnosed AFib. Primary care physicians see patients with palpitations, dizziness, and stroke risk factors; making Zio as easy to order as a blood test (via EHR integration) expands the TAM from ~30M cardiology visits to ~500M primary care visits.
Adoption
Why it matters now
iRhythm (IRTC):
- Zio XT: 14-day continuous ECG patch, AI-powered analysis — the core product
- Zio AT: higher-acuity variant with real-time alerting/telemetry
- Aura platform: Epic EHR integration (highlighted at XGM 2026)
- Q1 2026: $199.4M revenue (+25.7% YoY); FY2026 guidance $875–885M
- Pipeline: Zio MCT (Mobile Cardiac Telemetry) — next-gen, expected 1H 2027
- Risk: June 2026 data breach (ransomware) — proprietary and PHI data exposed
Key trends
- AI upstream detection: Zio moving from cardiology to primary care — the AI does the initial screening, flagging only actionable findings for physician review
- Mobile cardiac telemetry (MCT): Real-time monitoring for higher-acuity patients — Zio AT today, Zio MCT in 2027 — competing with traditional telemetry services
- AFib detection as stroke prevention: Undiagnosed AFib causes 15–20% of ischemic strokes. Widespread screening (Zio for every 65+ patient) could prevent thousands of strokes annually — the public health case is strong, reimbursement is catching up
Key players
| Ticker | Company | Role |
|---|---|---|
| IRTC | iRhythm Technologies | Zio XT/AT — dominant AI-powered ECG patch; Zio MCT pipeline 2027 |
| MDT | Medtronic | LINQ insertable cardiac monitor — implantable, 3-year battery; competing modality |
| BSX | Boston Scientific | LUX-Dx insertable cardiac monitor — competing implantable approach |
Related Technologies
- Continuous Glucose Monitoring (CGM) — same "wearable + AI + recurring revenue" business model, different analyte
- Liquid Biopsy & Early Cancer Detection — same "AI diagnostics + clinical validation + guideline inclusion" moat structure
Public-market mapping
Company exposure is being validated.
This technology is in the research taxonomy, but no published Daily PXS stock currently has a sufficiently direct mapping. Candidate suppliers remain under review.
02
Technology questions
Direct answers about the technology, its infrastructure layer and mapped public stocks.
What is Remote Cardiac Monitoring?
Wearable ECG patches and mobile cardiac telemetry that enable continuous, remote detection of arrhythmias — primarily atrial fibrillation AFib , the most common cardiac arrhythmia affecting 33 million people globally. iRhythm's Zio patch…
Which universe and layer is Remote Cardiac Monitoring mapped to?
Remote Cardiac Monitoring is mapped to Healthspan Infrastructure across Maintain.
Which stocks are mapped to Remote Cardiac Monitoring?
Daily PXS currently maps 0 public stocks to Remote Cardiac Monitoring.